Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial

Authors

  • Paul J. Reading PhD, MRCP,

    Corresponding author
    1. Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom
    • Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK
    Search for more papers by this author
  • Anna K Luce BSc,

    1. Institute for the Health of the Elderly, Wolfson Research Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom
    Search for more papers by this author
  • Ian G. McKeith MD, FRCPsych

    1. Institute for the Health of the Elderly, Wolfson Research Centre, Newcastle General Hospital, Newcastle upon Tyne, United Kingdom
    Search for more papers by this author

Abstract

This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug. © 2001 Movement Disorder Society.

Ancillary